Literature DB >> 18254581

Synthesis, Copper(II) Complexation, (64)Cu-Labeling, and Bioconjugation of a New Bis(2-pyridylmethyl) Derivative of 1,4,7-Triazacyclononane.

Gilles Gasser1, Linda Tjioe, Bim Graham, Matthew J Belousoff, Stefanie Juran, Martin Walther, Jens-Uwe Künstler, Ralf Bergmann, Holger Stephan, Leone Spiccia.   

Abstract

A new ligand derivative of 1,4,7-triazacyclononane (TACN), 2-[4,7-bis(2-pyridylmethyl)-1,4,7-triazacyclononan-1-yl]acetic acid ( 6), has been synthesized and its complexation behavior toward Cu2+ ions investigated. The ligand 6 has been characterized by spectroscopic methods, and a molecular structure of a corresponding Cu(II) complex has been elucidated by single-crystal X-ray analysis. The suitability of 6 for conjugation to peptide substrates has been shown by amide coupling of 6 to the stabilized derivative of bombesin (BN), beta Ala-beta Ala-[Cha13, Nle14]BN(7-14), to give the conjugate 8. The free ligand 6 and the bioconjugate 8 were labeled with 64Cu2+, and the resulting complexes, 64Cu subset6 and 64Cu subset8 , were found to be stable in the presence of a large excess of a competing ligand (cyclam) or copper-seeking superoxide dismutase (SOD), as well as in rat plasma. Biodistribution studies of 64Cu subset8 in Wistar rats showed a high activity uptake into the pancreas (5.76 +/- 0.25 SUV, 5 min p.i.; 3.93 +/- 0.25 SUV, 1 h p.i.), which is the organ with high levels of gastrin-releasing peptide receptor (GRPR). This receptor is overexpressed in a large number of breast and prostate carcinomas. The novel 64Cu subset6 complex had a dominating influence on the nonspecific activity biodistribution of its BN conjugate, since the distribution data of 64Cu subset6 are similar to those of 64Cu subset8 . The 64Cu complexes exhibited a low activity accumulation in the liver tissue and an extensive renal clearance, which was distinctively different to the biodistribution of 64CuCl 2, suggesting that 64Cu subset6 does not undergo significant demetalation, but rather exhibits high in vivo stability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254581     DOI: 10.1021/bc700396e

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  13 in total

1.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 3.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

4.  In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors.

Authors:  Adam F Prasanphanich; Lauren Retzloff; Stephanie R Lane; Prasant K Nanda; Gary L Sieckman; Tammy L Rold; Lixin Ma; Said D Figueroa; Samantha V Sublett; Timothy J Hoffman; Charles J Smith
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

5.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

Review 6.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

7.  68Ga-Labeled [Leu13ψThz14]Bombesin(7-14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake.

Authors:  Lei Wang; Zhengxing Zhang; Helen Merkens; Jutta Zeisler; Chengcheng Zhang; Aron Roxin; Ruiyan Tan; François Bénard; Kuo-Shyan Lin
Journal:  Molecules       Date:  2022-06-11       Impact factor: 4.927

8.  Pycup--a bifunctional, cage-like ligand for (64)Cu radiolabeling.

Authors:  Eszter Boros; Elena Rybak-Akimova; Jason P Holland; Tyson Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Reza Latifi; Peter Caravan
Journal:  Mol Pharm       Date:  2013-12-11       Impact factor: 4.939

Review 9.  Positron emission tomography imaging of prostate cancer.

Authors:  Hao Hong; Yin Zhang; Jiangtao Sun; Weibo Cai
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

Review 10.  Radiolabelled peptides for oncological diagnosis.

Authors:  Peter Laverman; Jane K Sosabowski; Otto C Boerman; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.